BioSpace News Archive

SPR Therapeutics announced it has obtained clearance from the U.S. Food and Drug Administration (FDA) for expanded labeling, which increases the intended patient population of the SPRINT® PNS System, along with new advances to enhance and simplify the SPRINT PNS System’s lead securement mechanism.

Atara Biotherapeutics, Inc. reported the grant of 36,750 restricted stock units of Atara’s common stock to three newly hired employees and stock options to purchase an aggregate of 48,300 shares of Atara’s common stock to two such newly hired employees.

Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 50,250 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 8,000 shares of Arcutis’ common stock to seven newly hired employees.

ORIC Pharmaceuticals, Inc. announced that on February 1, 2023, ORIC granted a total of 35,596 non-qualified stock options and 5,948 restricted stock units to three new non-executive employees who began their employment with ORIC in January 2023.

Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, announced that the company granted equity awards to 4 new employees with a grant date of February 1, 2023, as equity inducement awards outside of the company’s 2022 Equity Incentive Plan and material to the employees’ acceptance of employment with the company.

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”) is pleased to announce that all resolutions were passed by the requisite majority at its annual general meeting (the “Meeting”) held earlier today.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Ablacon, Inc., an Ajax Health and Zeus Health-backed developer of an innovative mapping system to guide the treatment of atrial fibrillation (AF), announced today the 12-month results from the FLOW-AF trial (NCT04473963).

Tvardi Therapeutics, Inc. announced that the management team will present at the Guggenheim Securities Oncology Conference on Wednesday, February 8, 2023, in New York City as well as host one-on-one meetings throughout the day.

Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Pamela Bush, Ph.D., MBA, as Chief Business Officer. Dr. Bush will lead all business development, partnering and growth strategies for Predictive Oncology.